Atea Pharmaceuticals, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Atea is a clinical-stage biopharmaceutical company developing oral antiviral therapies. The unaudited report covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023. Lead programs are bemnifosbuvir for COVID-19 and bemnifosbuvir combined with ruzasvir for hepatitis C virus (HCV).
- SUNRISE-3 Phase 3 COVID-19 trial enrollment was completed in March 2024, with 2,221 patients in the supportive-care monotherapy cohort and 74 in the combination-antiviral cohort.
- The HCV Phase 2 trial is enrolling up to approximately 280 treatment-naive patients. The 60-patient lead-in cohort produced a 98% SVR4 rate, or 58 of 59 evaluable patients.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $57.6 million | $29.0 million | +$28.6 million |
| General and administrative expense | $12.2 million | $12.6 million | -$0.4 million |
| Total operating expenses | $69.8 million | $41.6 million | +$28.2 million |
| Interest income and other, net | $6.9 million | $6.3 million | +$0.6 million |
| Net loss | $63.2 million | $35.5 million | Loss increased by $27.7 million |
| Net loss per share | $0.75 | $0.43 | Loss per share increased |
| Net cash used in operating activities | $39.9 million | $29.9 million | Use increased by $10.0 million |
Because Atea has no product revenue, conventional revenue-based margins are not meaningful. The operating loss equaled operating expenses, and the company remains dependent on financing and investment income.
- Cash, cash equivalents and marketable securities totaled $541.5 million at March 31, 2024, including $160.9 million of cash and cash equivalents and $380.6 million of marketable securities.
- Total assets were $553.0 million and stockholders’ equity was $504.4 million. Accumulated deficit was $259.0 million.
- The filing reports no borrowings or debt financing; liabilities primarily consisted of accounts payable, accrued expenses, income taxes payable and operating lease liabilities.
- Marketable securities were primarily U.S. Treasury obligations, U.S. government agency securities, commercial paper and corporate bonds, all with remaining maturities of one year or less.
- Management believes available liquidity is sufficient to fund planned operations into 2027, although this estimate depends on assumptions that may prove incorrect.
Material changes versus the prior comparable period
- R&D expense nearly doubled, primarily due to higher external costs for the Phase 3 SUNRISE-3 COVID-19 trial and the HCV Phase 2 program. COVID-19 external costs increased to $39.3 million from $8.9 million, while HCV external costs increased to $6.0 million from $3.4 million.
- Dengue external costs fell to zero from $3.3 million, consistent with the company’s decision not to pursue further development of AT-752 for dengue.
- Net loss increased 78% to $63.2 million, while operating cash burn increased 34% to $39.9 million.
- Interest income increased because of higher interest rates and investment in higher-yielding marketable securities.
- Accounts payable increased to $21.1 million from $4.3 million at December 31, 2023, while accrued expenses declined to $19.4 million from $27.4 million.
- Common shares outstanding increased to 84.2 million from 83.4 million, primarily reflecting equity award vesting and employee stock plan activity. The company issued no shares under its $200 million at-the-market sales agreement.
Guidance, outlook, risks and unusual items
- Management expects to report SUNRISE-3 results in the second half of 2024.
- Final SVR12 results from the global HCV Phase 2 study are expected in the second half of 2024. If successful and aligned with regulators, Atea anticipates initiating HCV Phase 3 development in the second half of 2024.
- The company expects to remain unprofitable and generate no product revenue for the foreseeable future. It expects significant additional spending on clinical development, manufacturing, regulatory preparation and potential commercialization.
- The COVID-19 trial faces substantial endpoint risk because hospitalization and death rates have declined. A lower-than-expected event rate could cause the study to fail to meet its primary endpoint despite completion of enrollment.
- Bemnifosbuvir faces competition from approved or authorized COVID-19 treatments, including Paxlovid, Lagevrio and Veklury, as well as emerging therapies and vaccines. The evolving virus and changing treatment landscape could reduce the product’s market opportunity.
- Atea relies heavily on CROs and CMOs, including a sole Chinese supplier of ruzasvir active pharmaceutical ingredient and Chinese suppliers of regulatory starting materials. Supply, regulatory, geopolitical and manufacturing disruptions could delay development.
- Gilead Sciences’ U.S. Patent No. 11,642,361 purports to cover bemnifosbuvir. The PTAB declined in February 2024 to institute Atea’s post-grant review petition. Atea may need to obtain a license if the patent is upheld and Gilead asserts it.
- Under the Merck license for ruzasvir, the first potential development milestone is $5.0 million upon commencement of a Phase 3 trial, in addition to tiered royalties on future net sales.
- Roche credits reduced R&D expense by $1.3 million in Q1 2024; management does not anticipate additional credits.
- No material legal proceedings were reported. Disclosure controls and procedures were deemed effective at the reasonable assurance level, with no material changes in internal control over financial reporting.
Most important facts for investors to verify
- Timing and statistical outcome of the SUNRISE-3 primary endpoint results expected in the second half of 2024.
- Completion, safety profile and final SVR12 results of the bemnifosbuvir/ruzasvir HCV Phase 2 program.
- Whether the reported liquidity runway into 2027 remains valid as clinical, manufacturing and commercialization costs evolve.
- Potential implications of Gilead’s ’361 patent for commercialization, licensing costs or litigation exposure.
- Reliability and geographic concentration of third-party manufacturing and supply arrangements, particularly in China.
- Future dilution risk from the $200 million sales agreement, equity awards and potential additional financing.
- Whether declining COVID-19 hospitalization and death rates, variant changes and competitive treatments reduce the commercial opportunity or affect trial interpretability.